Database : MEDLINE
Search on : Photosensitivity and Disorders [Words]
References found : 6256 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 626 go to page                         

  1 / 6256 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29485795
[Au] Autor:Lugovic-Mihic L; Duvancic T; Fercek I; Vukovic P; Japundzic I; Cesic D
[Ad] Address:Clinical Department of Dermatovenereology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
[Ti] Title:Drug-Induced Photosensitivity - a Continuing Diagnostic Challenge.
[So] Source:Acta Clin Croat;56(2):277-283, 2017 Jun.
[Is] ISSN:0353-9466
[Cp] Country of publication:Croatia
[La] Language:eng
[Ab] Abstract:When taking different drugs, their possible side effects on the skin should be considered, including skin reactions connected to photosensitivity. This photosensitivity caused by drugs can appear as phototoxic reactions (which occur more often) or photoallergic reactions (which occur less often and include allergic mechanisms). The following drugs stand out as medications with a high photosensitivity potential: nonsteroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs (such as amiodarone), phenothiazines (especially chlorpromazine), retinoids, antibiotics (sulfonamides, tetracyclines, especially demeclocycline and quinolones), etc. In recent years, photosensitive reactions to newer drugs have appeared, e.g., targeted anticancer therapies such as BRAF kinase inhibitors (vemurafenib, dabrafenib), EGFR inhibitors, VEGFR inhibitors, MEK inhibitors, Bcr-Abl tyrosine kinase inhibitors, etc. In patients taking drugs over a longer period of time (e.g., NSAIDs, cardiovascular drugs, etc.), a particular problem arises when an unrecognized drug-induced photosensitivity on the skin manifests in summer months. When taking patient histories, the physician/dermatovenereologist should bear in mind that any drug the patient is currently taking may be the cause of skin reactions. Therefore, patients who use potentially photosensitive drugs and treatments on a long term basis should be warned of the possibility of these side effects on their skin and advised to avoid direct exposure to sunlight and to use adequate photoprotection. If patients carefully protect themselves from the sun, it is often not necessary to stop treatments that include photosensitive drugs. If such reactions appear, anti-inflammatory and antiallergic therapies should be introduced.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process
[do] DOI:10.20471/acc.2017.56.02.11

  2 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29274161
[Au] Autor:Borges JF; Lanaro ND; Bernardo VG; Albano RM; Dias F; de Faria PA; Pinto LF; Lourenço SQ
[Ad] Address:Av. das Acacias, 150, bl.01, ap. 104 Barra da Tijuca, RJ, Brazil 22776000, silourenco2015@gmail.com.
[Ti] Title:Lower lip squamous cell carcinoma in patients with photosensitive disorders: Analysis of cases treated at the Brazilian National Cancer Institute (INCA) from 1999 to 2012.
[So] Source:Med Oral Patol Oral Cir Bucal;23(1):e7-e12, 2018 Jan 01.
[Is] ISSN:1698-6946
[Cp] Country of publication:Spain
[La] Language:eng
[Ab] Abstract:BACKGROUND: Lower lip squamous cell carcinoma (LLSCC) is a common malignancy of the head and neck, being mainly a consequence of a chronic exposure to ultraviolet (UV) light solar radiation. Here, we evaluated the clinicopathological profile of patients with photosensitive disorders (xeroderma pigmentosum, lupus erythematosus and albinism) that developed LLSCC. MATERIAL AND METHODS: Data from patients who had a diagnosed LLSCC with a prior xeroderma pigmentosum, lupus erythematosus or albinism diagnosis that were treated at INCA from 1999 to 2012 were collected from patients medical records (n=16). The control group was composed of 68 patients with LLSCC without a medical history of photosensitivity. The clinicopathological data of this study population were collected and the association between these variables was analyzed by Fisher's exact test. Survival curves were constructed using the Kaplan-Meier method and compared by log-rank test. All statistical analyses were performed using SPSS statistics package. RESULTS: The mean age of patients in the photosensitive and non-photosensitive groups was 42 years and 67 years, respectively (p<0.0001). A previous history of malignant diseases was more common in the photosensitive group (p=0.001). In both groups, most tumors showed a pathological stage I/II disease. Overall and cancer-specific survival were not statistically different. However, disease-free interval showed a significant difference (p=0.01) between the photosensitive and non-photosensitive patients. CONCLUSIONS: Photosensitive patients presented LLSCC at earlier age but it usually was not the primary tumor in these patients. Furthermore, a more aggressive pathological behavior was not seen when compared with tumors from non-photosensitive patients. The disease-free interval was lower in photosensitive patients, as expected.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process
[do] DOI:10.4317/medoral.21960

  3 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29325823
[Au] Autor:Garcia-Lainez G; Martínez-Reig AM; Limones-Herrero D; Consuelo Jiménez M; Miranda MA; Andreu I
[Ad] Address:Instituto de Investigación Sanitaria (IIS) La Fe, Hospital Universitari i Politècnic La Fe, Avenida de Fernando Abril Martorell 106, 46026 Valencia, Spain.
[Ti] Title:Photo(geno)toxicity changes associated with hydroxylation of the aromatic chromophores during diclofenac metabolism.
[So] Source:Toxicol Appl Pharmacol;341:51-55, 2018 Feb 15.
[Is] ISSN:1096-0333
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Diclofenac (DCF) can cause adverse reactions such as gastrointestinal, renal and cardiovascular disorders; therefore, topical administration may be an attractive alternative to the management of local pain in order to avoid these side effects. However, previous studies have shown that DCF, in combination with sunlight, displays capability to induce photosensitivity disorders. In humans, DCF is biotransformed into hydroxylated metabolites at positions 4' and 5 (4'OH-DCF and 5OH-DCF), and this chemical change produces non negligible alterations of the drug chromophore, resulting in a significant modification of its light-absorbing properties. In the present work, 5OH-DCF exhibited higher photo(geno)toxic potential than the parent drug, as shown by several in vitro assays (3T3 NRU phototoxicity, DNA ssb gel electrophoresis and COMET), whereas 4'OH-DCF did not display significant photo(geno)toxicity. This could be associated, at least partially with their more efficient UV-light absorption by 5OH-DCF metabolite and with a higher photoreactivity. Interestingly, most of the cellular DNA damage photosensitized by DCF and 5OH-DCF was repaired by the cells after several hours, although this effect was not complete in the case of 5OH-DCF.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180211
[Lr] Last revision date:180211
[St] Status:In-Data-Review

  4 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29305302
[Au] Autor:Bukowska B; Karwowski BT
[Ad] Address:Food Science Department, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland. Electronic address: barbara.bukowska@umed.lodz.pl.
[Ti] Title:Actual state of knowledge in the field of diseases related with defective nucleotide excision repair.
[So] Source:Life Sci;195:6-18, 2018 Feb 15.
[Is] ISSN:1879-0631
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Xeroderma pigmentosum (XP), trichothiodystrophy (TTD) and Cockayne syndrome (CS) are rare genetic diseases characterized by a large range of clinical symptoms. However, they are all associated with defects in nucleotide excision repair (NER), the system responsible for removing bulky DNA lesions such as those generated by UV light: cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone photoproducts (6-4 PPs). Over the past years, detailed structural and biochemical information on NER-associated proteins has emerged. In the first part of the article we briefly present the main steps of the NER pathway with an emphasis on the precise role of certain proteins. Further, we focus on clinical manifestations of the disorders and describe the diagnostic procedures. Then we consider how current therapy and advanced technology could improve patients' quality of life. Although to date the discussed diseases remain incurable, effective sun protection, a well thought out diet, and holistic medical care provide longer life and better health. This review summarizes the current state of knowledge regarding the epidemiology of NER-associated diseases, their genetic background, clinical features, and treatment options.
[Mh] MeSH terms primary: DNA Repair/genetics
DNA Repair/physiology
Genetic Diseases, Inborn/genetics
[Mh] MeSH terms secundary: Animals
Cockayne Syndrome/genetics
Humans
Trichothiodystrophy Syndromes/genetics
Xeroderma Pigmentosum/genetics
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180208
[Lr] Last revision date:180208
[Js] Journal subset:IM
[Da] Date of entry for processing:180107
[St] Status:MEDLINE

  5 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29174026
[Au] Autor:Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
[Ad] Address:Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
[Ti] Title:Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
[So] Source:Nutr Metab Cardiovasc Dis;27(12):1098-1107, 2017 Dec.
[Is] ISSN:1590-3729
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND AND AIMS: We assessed post-marketing safety of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) by analyzing adverse events (AEs) reported in international pharmacovigilance databases. METHODS AND RESULTS: Eudravigilance, WHO-Vigibase (as of Feb 25, 2017) and the FDA Adverse Event Reporting System (FAERS, from 2004 to 2016 second quarter) were queried to extract AEs recording SGLT2-Is as suspect. Disproportionality analyses (case/non-case method) were performed in FAERS by calculating the reporting odds ratios (RORs) from System Organ Classes (SOCs) to Preferred Terms (PTs) (precise clinical entities). Potential signals were defined by statistically-significant ROR (lower limit of the 95% confidence interval - LL95%CI - >1) undetected by literature analysis (as of December 2016). SGLT2-Is were recorded in 7972, 19,775, 11,137 reports (Eudravigilance, WHO-Vigibase and FAERS, respectively); in FAERS, statistically significant ROR emerged for the following SOCs: "infections and infestations" (N = 2162; LL95%CI = 3.25), "metabolism and nutrition disorders" (2278; 1.36), "renal and urinary disorders" (1665; 2.31), "reproductive system and breast disorders" (471; 4.85), "skin and subcutaneous tissue disorders" (1136; 1.52). Skin toxicity emerged as potential signal (e.g., rash, photosensitivity, urticaria as PTs), both for SGLT2-Is as a class and as individual drugs. Severe adverse skin events (81 reports, 7% of the skin cases) mainly occurred in females aged 18-65 using SGLT2-Is as single antidiabetic regimen. CONCLUSION: Among antidiabetics, SGLT2-Is are associated with higher reporting of infections, metabolism, renal and reproductive AEs, corroborating clinical trial evidence. Their large reporting patterns and the unexpected signal of skin toxicity justify active vigilance by clinicians and "real-time" monitoring by pharmacovigilance experts.
[Mh] MeSH terms primary: Adverse Drug Reaction Reporting Systems
Diabetes Mellitus, Type 2/drug therapy
Drug-Related Side Effects and Adverse Reactions/epidemiology
Hypoglycemic Agents/adverse effects
Pharmacovigilance
Sodium-Glucose Transporter 2/antagonists & inhibitors
[Mh] MeSH terms secundary: Adolescent
Adult
Aged
Child
Child, Preschool
Databases, Factual
Diabetes Mellitus, Type 2/metabolism
Drug-Related Side Effects and Adverse Reactions/diagnosis
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Patient Safety
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2/metabolism
Time Factors
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Hypoglycemic Agents); 0 (SLC5A2 protein, human); 0 (Sodium-Glucose Transporter 2)
[Em] Entry month:1712
[Cu] Class update date: 171218
[Lr] Last revision date:171218
[Js] Journal subset:IM
[Da] Date of entry for processing:171128
[St] Status:MEDLINE

  6 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29199239
[Au] Autor:Nakao S; Hatahira H; Sasaoka S; Hasegawa S; Motooka Y; Ueda N; Abe J; Fukuda A; Naganuma M; Kanoh H; Seishima M; Ishiguro M; Kinosada Y; Nakamura M
[Ad] Address:Laboratory of Drug Informatics, Gifu Pharmaceutical University.
[Ti] Title:Evaluation of Drug-Induced Photosensitivity Using the Japanese Adverse Drug Event Report (JADER) Database.
[So] Source:Biol Pharm Bull;40(12):2158-2165, 2017.
[Is] ISSN:1347-5215
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:Drug-induced photosensitivity (DIP) refers to the development of cutaneous disorders caused by the combined effects of different medications and light. The aim of this study was to obtain new information on drug risk comparisons and on DIP onset profiles, including seasonal variations, for clinically used prescription drugs. We analyzed reports of DIP recorded in the Japanese Adverse Drug Event Report (JADER) database using a reporting odds ratio (ROR). We also used Weibull proportional-hazards models for each drug to examine the patterns of DIP. The JADER database contains 430587 reports recorded from April 2004 to November 2016. The ROR values (95% confidence interval [CI]) of losartan/hydrochlorothiazide (HCTZ), valsartan/HCTZ, and ketoprofen were 214.5 (162.1-283.9), 104.7 (66.3-165.5), and 117.9 (76.6-181.5), respectively. For time-to-onset analysis, the median durations (interquartile range) for DIP caused by losartan/HCTZ, valsartan/HCTZ, and ketoprofen were 56 (41-78), 49 (38-88), and 8 (2-14) days, respectively. The lower limit of the 95% CI for the Weibull shape parameter ß value for losartan/HCTZ was greater than 1. More than half of the reports of DIP onset following the administration of ketoprofen were recorded within 10 d of treatment initiation. The seasonal variation of photosensitivity reactions was shown to follow an annual sinusoidal pattern with a peak in April and May. Based on the results, losartan/HCTZ, valsartan/HCTZ, and ketoprofen should be used carefully in clinical practice to avoid DIP.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 171204
[Lr] Last revision date:171204
[St] Status:In-Process
[do] DOI:10.1248/bpb.b17-00561

  7 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29171397
[Au] Autor:Dragoumi P; Emery J; Chivers F; Brady M; Desurkar A; Cross JH; Das KB
[Ad] Address:Aristotle University of Thessaloniki, A' Department of Paediatrics, Hippokration General Hospital of Thessaloniki, Greece.
[Ti] Title:Crossing the lines between epilepsy syndromes: a myoclonic epilepsy variant with prominent eyelid myoclonia and atonic components.
[So] Source:Epileptic Disord;, 2017 Nov 24.
[Is] ISSN:1950-6945
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:Accurate diagnosis of a distinct epilepsy syndrome is based on well-defined electroclinical features that differentiate separate nosological entities. In clinical practice, however, syndromes may overlap and cases may present with unusual manifestations posing a diagnostic challenge. This heterogeneity has been documented in several cases presenting with eyelid myoclonia with or without absences (EMA) diagnosed either as Jeavons syndrome (JS) variants or as genetic generalised epilepsies defined by the presence of this unique clinical entity. The hallmark of JS is the triad: (1) eyelid myoclonia with or without absences, (2) eye closure-induced paroxysms, and (3) photosensitivity. The presence of massive myoclonus, intellectual disability, or slowing of the EEG background are not typical features of the syndrome and may cause delay in making the correct diagnosis. Adding to the variability of clinical features, we describe two female paediatric patients with probable genetic epilepsy who presented with EMA but demonstrated clear atypical features, such as prominent myoclonic seizures, atonic components on video-EEG, and cognitive impairment. We also note the presence of interictal and ictal posterior discharges during eyelid myoclonia in one, supporting similar previous observations leading to consideration of EMA as an occipital cortex-initiated seizure activity. [Published with video sequences on www.epilepticdisorders.com].
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171124
[Lr] Last revision date:171124
[St] Status:Publisher
[do] DOI:10.1684/epd.2017.0937

  8 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29131317
[Au] Autor:Lawrence KP; Gacesa R; Long PF; Young AR
[Ad] Address:St John's Institute of Dermatology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
[Ti] Title:Molecular photoprotection of human keratinocytes in vitro by the naturally occurring mycosporine-like amino acid (MAA) palythine.
[So] Source:Br J Dermatol;, 2017 Nov 13.
[Is] ISSN:1365-2133
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Solar ultraviolet radiation (UVR) induces molecular and genetic changes in the skin, which result in skin cancer, photoageing and photosensitivity disorders. The use of sunscreens is advocated to prevent such photodamage, however most formulations contain synthetic UVR filters that are non-biodegradable and can damage fragile marine ecosystems. Mycosporine-like amino acids (MAA) are natural UVR-absorbing compounds that have evolved in marine species for protection against chronic UVR exposure in shallow-water habitats. OBJECTIVES: To determine if palythine, a photostable model MAA, could offer protection against a range of UVR-induced damage biomarkers that are important in skin cancer and photoageing. METHODS: HaCaT human keratinocytes were used to assess the photoprotective potential of palythine using a number of endpoints including cell viability, DNA damage (non-specific, cyclobutane pyrimidine dimers and oxidatively generated damage), gene expression changes (linked to inflammation, photoageing and oxidative stress) and oxidative stress. The anti-oxidant mechanism was investigated using chemical quenching and Nrf2 pathway activation assays. RESULTS: Palythine offered statistically significant protection (p<0.005) against all endpoints tested even at extremely low concentrations (0.3% w/v). Additionally, palythine was found to be a potent antioxidant, reducing oxidatively generated stress, even when added post exposure. CONCLUSIONS: Palythine is an extremely effective multifunctional photoprotective molecule in vitro that has potential to be developed as a natural and biocompatible alternative to synthetic UVR filters. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171113
[Lr] Last revision date:171113
[St] Status:Publisher
[do] DOI:10.1111/bjd.16125

  9 / 6256 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28964535
[Au] Autor:Levoska MA; Cohen JI; Manoli I; Richard Lee CC; Ching SST; Shand J; Tamura D; Kraemer KH; DiGiovanna JJ
[Ad] Address:Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Medical Research Scholars Program, National Institutes of Health, Bethesda, Maryland.
[Ti] Title:Recurrent scarring papulovesicular lesions on sun-exposed skin in a 22-year-old man.
[So] Source:J Am Acad Dermatol;, 2017 Sep 27.
[Is] ISSN:1097-6787
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:KEY TEACHING POINTS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171001
[Lr] Last revision date:171001
[St] Status:Publisher

  10 / 6256 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28848724
[Au] Autor:Taghdiri M; Dastsooz H; Fardaei M; Mohammadi S; Farazi Fard MA; Faghihi MA
[Ad] Address:Genetic Counseling Center, Shiraz Welfare Organization, Shiraz, Iran.
[Ti] Title:A Novel Mutation in Gene Causing Cockayne Syndrome.
[So] Source:Front Pediatr;5:169, 2017.
[Is] ISSN:2296-2360
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:Cockayne syndrome (CS) is a rare autosomal recessive multisystem disorder characterized by impaired neurological and sensory functions, cachectic dwarfism, microcephaly, and photosensitivity. This syndrome shows a variable age of onset and rate of progression, and its phenotypic spectrum include a wide range of severity. Due to the progressive nature of this disorder, diagnosis can be more important when additional signs and symptoms appear gradually and become steadily worse over time. Therefore, mutation analysis of genes involved in CS pathogenesis can be helpful to confirm the suspected clinical diagnosis. Here, we report a novel mutation in gene in a 16-year-old boy who suffers from poor weight gain, short stature, microcephaly, intellectual disability, and photosensitivity. The patient was born to consanguineous family with no previous documented disease in his parents. To identify disease-causing mutation in the patient, whole exome sequencing utilizing next-generation sequencing on an Illumina HiSeq 2000 platform was performed. Results revealed a novel homozygote mutation in gene (NM_000082: exon 11, c.1122G>C) in our patient. Another gene ( ), which is also involved in CS did not have any disease-causing mutations in the proband. The new identified mutation was then confirmed by Sanger sequencing in the proband, his parents, and extended family members, confirming co-segregation with the disease. In addition, different bioinformatics programs which included MutationTaster, I-Mutant v2.0, NNSplice, Combined Annotation Dependent Depletion, The PhastCons, Genomic Evolutationary Rate Profiling conservation score, and T-Coffee Multiple Sequence Alignment predicted the pathogenicity of the mutation. Our study identified a rare novel mutation in gene and help to provide accurate genetic counseling and prenatal diagnosis to minimize new affected individuals in this family.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1708
[Cu] Class update date: 170902
[Lr] Last revision date:170902
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.3389/fped.2017.00169


page 1 of 626 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information